Dmytro Kharkov

Why is Hims & Hers Health stock down 3.5% today?

Why is Hims & Hers Health stock down 3.5% today?
Hims & hers slides 3.56% today

Hims & Hers Health Inc (HIMS) fell 3.56% as skepticism around its recent Peptides+ product launch and regulatory risks weighed on sentiment. The decline is reinforced by the stock trading well below its key moving averages, in line with sustained selling pressure across time frames.

HIMS price prediction
24H -2.05%
$14.3
48H -3.36%
$14.11
7D -4.93%
$13.88
1M -48.29%
$7.55
3M -61.1%
$5.68
6M -76.92%
$3.37
12M -65.89%
$4.98
Current price: $14.6 -1.4200 8.86%
Closed 11/20
Daily range 14.51 Arrow from to Icon 15.96
Weekly range 14.51 Arrow from to Icon 19.17
Loading...

Highlights

  • Hims & Hers Health introduced Peptides+, a new range of compounded peptide and longevity treatments prepared in US pharmacies without FDA approval.
  • The launch has led to regulatory and reputational concerns, with questions raised about the efficacy and safety of non-FDA-approved treatments.
  • Shares of Hims & Hers Health trade below key moving averages with strong sell signals from technical indicators and a projected range of $13.85 to $17.04 for the week.

Peptide debut increases regulatory scrutiny amid persistent investor skepticism

Hims & Hers Health launched Peptides+, a new line of compounded peptide and longevity treatments, after recent regulatory changes allowed the initial sale of five non-FDA-approved products prepared in licensed U.S. pharmacies. The initiative marks a strategic move into the peptide market under the company's chief medical officer, with plans for further expansion. The launch has raised regulatory and reputational concerns due to the lack of FDA approval, as investor sentiment faced additional headwinds from questions about the efficacy and safety of the treatments, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes growing skepticism toward Hims & Hers Health after the Peptides+ launch. He highlights that the stock remains vulnerable, trading well below all major moving averages. Bearish technical indicators reinforce negative sentiment, with momentum tools signaling strong sell bias. Kharitonov sees additional regulatory risk weighing on confidence and expects downside pressure to persist. "Regulatory uncertainties combined with weak technical structure suggest investors should remain cautious at these levels."
Viktoras Karapetjanc, expert at Traders Union, views Hims & Hers Health’s entry into peptides as a bold and strategic expansion. He believes the recent volatility creates tactical opportunities within a fast-evolving healthcare market. Despite near-term skepticism, Karapetjanc sees the company’s innovation pipeline underscoring long-term prospects. He emphasizes that decisive moves above resistance could attract new flows. "A breakthrough in regulatory acceptance or sentiment could rapidly shift the outlook in favor of HIMS bulls."
Sholanke Dele, market strategist, sees sentiment sharply negative after the Peptides+ launch. Risk perception is elevated as investors question safety and regulatory compliance. Intraday flows remain heavily skewed toward sellers, amplifying short-term pressure. "Current market mood signals that participants remain unconvinced by the company’s recent move and are bracing for further downside."
Hims & Hers Health Inc. asset chart
Hims & Hers Health Inc. price dynamics. Source: TradingView.

Bearish structure deepens as momentum signals confirm downside pressure

Hims & Hers Health remains under marked pressure, with the current price at $15.45, trading below the MA-20 at $23.46, MA-50 at $26.77, and MA-200 at $26.51. This setup signals a bearish structure across short-, medium-, and long-term horizons. The nearest resistance stands at $15.98, while support is found at $13.85. Momentum indicators, including the MACD and ADX, show a strong sell bias. Both the Relative Strength Index (RSI) and Stochastic RSI are in the oversold zone, confirmed by a negative reading in the Commodity Channel Index (CCI). Bull/Bear Power (BBP) and the Awesome Oscillator both confirm that sellers dominate intraday action. The stock dropped $0.57 or 3.56% after an initial upside gap at the open, and volatility for the day reached 8.14%, with the overall tone remaining heavy.

Earlier, analysts noted that Hims & Hers Health was experiencing sustained bearish momentum, reinforced by regulatory risks and lackluster sentiment following its non-FDA-approved product launches. The latest technical structure and price action confirm this downside bias, with traders advised to monitor $15.98 as key resistance and $13.85 as crucial support in an environment dominated by seller control.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.